secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0000879169-22-000007
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte Q3 product rev $713M (+20%); Jakafi guidance raised to $2.38-2.40B; Opzelura $38M
--------------------------------------------------------------------------------

- Total product revenues $713M (+20% YoY); Jakafi $620M (+13%); Opzelura $38M ($0 prior year).
- GAAP diluted EPS $0.50 (vs $0.82 YoY); Non-GAAP diluted EPS $0.60 (vs $1.18).
- Jakafi FY22 guidance low end raised to $2.38-2.40B; other Hem/Onc rev guidance lowered to $200-210M on FX.
- Pending acquisition of Villaris (auremolimab anti-IL-15Rβ mAb) for vitiligo; clinical start 2023.
- Pipeline: once-daily ruxolitinib XR PDUFA Mar 23, 2023; axatilimab cGVHD results mid-2023; povorcitinib Ph3 HS end-2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000087916922000007/0000879169-22-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000087916922000007/incy-20221101.htm
  HTML page:      https://secwatch.observer/filing/0000879169-22-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer